4.74
0.08 (1.72%)
| Previous Close | 4.66 |
| Open | 4.67 |
| Volume | 1,150,359 |
| Avg. Volume (3M) | 1,402,577 |
| Market Cap | 616,120,576 |
| Price / Sales | 2.90 |
| Price / Book | 1.88 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2026 |
| Profit Margin | -5.71% |
| Operating Margin (TTM) | -36.12% |
| Diluted EPS (TTM) | -0.090 |
| Quarterly Revenue Growth (YOY) | -7.60% |
| Quarterly Earnings Growth (YOY) | 75.20% |
| Total Debt/Equity (MRQ) | 4.19% |
| Current Ratio (MRQ) | 5.62 |
| Operating Cash Flow (TTM) | 21.30 M |
| Levered Free Cash Flow (TTM) | 30.18 M |
| Return on Assets (TTM) | -3.51% |
| Return on Equity (TTM) | -2.91% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Cytek Biosciences, Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 2.0 |
| Average | 1.17 |
|
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Core |
| % Held by Insiders | 9.15% |
| % Held by Institutions | 62.13% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |